Last reviewed 2026-05-22 · How we verify

Clopradone (ETOPERIDONE)

Phase 2 active Small molecule ✓ Verified May 2026

Clopradone (generic name: ETOPERIDONE) is a Selective Serotonin Reuptake Inhibitors drug. It is currently in Phase 2 development.

Clopradone works by blocking the reabsorption of serotonin in the brain, allowing more of this neurotransmitter to be available for communication between nerve cells.

Clopramone is a small molecule. It is also known by the synonyms Etoperidona, Etoperidone, and Etoperidone.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ETOPERIDONE
Drug class	Selective Serotonin Reuptake Inhibitors
Target	5-hydroxytryptamine receptor 1A, D(2) dopamine receptor, Histamine H1 receptor
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

Imagine your brain is a network of messengers, and serotonin is one of the key messengers that helps you feel happy and calm. When you take Clopradone, it helps prevent these messengers from being taken back in, so there are more of them available to help you feel better.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Clopradone CI brief — competitive landscape report
Clopradone updates RSS · CI watch RSS

Frequently asked questions about Clopradone

What is Clopradone?

Clopradone (ETOPERIDONE) is a Selective Serotonin Reuptake Inhibitors drug.

How does Clopradone work?

Clopradone works by blocking the reabsorption of serotonin in the brain, allowing more of this neurotransmitter to be available for communication between nerve cells.

What is the generic name of Clopradone?

ETOPERIDONE is the generic (nonproprietary) name of Clopradone.

What drug class is Clopradone in?

Clopradone belongs to the Selective Serotonin Reuptake Inhibitors class. See all Selective Serotonin Reuptake Inhibitors drugs at /class/selective-serotonin-reuptake-inhibitors.

What development phase is Clopradone in?

Clopradone is in Phase 2.

What does Clopradone target?

Clopradone targets 5-hydroxytryptamine receptor 1A, D(2) dopamine receptor, Histamine H1 receptor and is a Selective Serotonin Reuptake Inhibitors.

Drug class: All Selective Serotonin Reuptake Inhibitors drugs
Target: All drugs targeting 5-hydroxytryptamine receptor 1A, D(2) dopamine receptor, Histamine H1 receptor
Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing